YD Bio Limited (YDES) is a Nasdaq-listed, Taipei-based biotechnology company with roughly 15 employees and a market value near $340 million. It operates DNA methylation-based oncology testing programs in the United States, supplies drugs and materials for clinical trials, and commercializes ophthalmic products such as 3D LensMate artificial tears and eye drops. Its shares have traded publicly only since mid-2025, and its free float is small — about 16.2 million shares, with insiders holding the large majority.
The stock was quoted at $4.80 shortly after 10:15 a.m. Eastern on Wednesday, up 1.48% from Tuesday's close of $4.73. That prior close was itself a decline of 2.07% from Monday's $4.83. The direction is modestly higher, but the move is well below the 3% threshold that would normally qualify as a significant session — and no verified catalyst has been identified for it.
No verified news or fundamental catalyst found after reviewing company releases, regulatory filings, wire coverage and analyst commentary. The most recent material disclosure came on November 12, when YD Bio announced that the U.S. Food and Drug Administration had granted its INTERACT meeting request for YDB-LMSCEV-001, an investigational extracellular-vesicle eye drop for dry eye disease. That release preceded a sharp 15.5% decline in the following session, and it is too distant and too small in market impact to account for Wednesday's drift higher.
What the trading record does support is a technical explanation. The stock has lost about 20% in five sessions and roughly 61% year to date, leaving it deeply oversold relative to its own moving averages and prone to reflexive bounces. Wednesday's action fits that pattern: a rapid push to $5.265 on a handful of small lots, followed by an equally fast fade back to $4.80. With an average daily turnover of roughly 0.2% of shares outstanding and a spread that has recently quoted near $4.15 bid against $7.00 offered, the order book is thin enough that individual orders of a few hundred shares can move the tape by several percent. The move is consistent with speculative, liquidity-driven trading rather than a reassessment of fundamentals.
Participation was conspicuously light. Roughly 12,850 shares had traded by mid-morning, a fraction of the 78,600-share 10-day average and far below the 311,000-share three-month average. Dollar volume was only about $63,000, and the session's range of $4.80 to $5.265 produced an amplitude near 9.8% — a wide band for a stock that finished up less than 2%.
The broader tape offered no tailwind. The S&P 500 proxy was down about 0.3% and the small-cap benchmark was up roughly 0.3%, while the biotech sector ETF was essentially flat. The absence of a shared sector catalyst reinforces the view that Wednesday's movement was idiosyncratic to YD Bio and driven by the mechanics of a thin float. Technically, shares remain trapped below the 50-day and 200-day averages and are hovering just above the lower half of a 52-week range that stretches from $1.70 to $15.72, with the $5.00 round number acting as immediate resistance after rejecting the stock intraday.
The score runs from 0 to 100, where 0 means no meaningful news and a price move that is entirely normal for the stock, and 100 means transformative news paired with an extreme, rare move. YD Bio receives a score of 3 out of 100.
Verified news was effectively absent: no filings, contracts, financings or analyst actions accompanied the session, and the prior week's FDA correspondence was already fully public. The price behavior was equally unremarkable. Over the past 60 sessions the stock has averaged an absolute daily move of about 8.9%, and Wednesday's 1.48% change is roughly one-sixth of that. Moves of 1.48% or more occurred in 54 of those 60 sessions, so this is ordinary noise for this security rather than an anomaly. Weak news and routine price action combine to produce a low score.
The key scheduled item is the FDA's written response on YDB-LMSCEV-001, expected by January 4, 2027, covering seven manufacturing and control questions and two early animal-study design questions. Management has said it will use that feedback to refine manufacturing and non-clinical plans before requesting a pre-IND meeting — a lengthy pathway that leaves the program years from any potential commercialization.
On the financial side, the last reported results came on August 31, 2026, for the six months ended June 30. Revenue remains minimal relative to the company's valuation, operating cash flow is negative, and cash stood at roughly $2.7 million at the most recent quarter — a thin cushion that keeps dilution risk on the table. Sell-side coverage is sparse, so expectations are difficult to anchor. Additional variables include progress on the OkaiDx laboratory-developed test rollout and the pending Safe Save Medical letter of intent. The principal risks are financing needs, execution on a very small operating base, low liquidity, and the outsized sensitivity of a 16-million-share float to modest order flow.
Tickeron offers hundreds of AI trading bots that cover thousands of tickers across global markets, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics and traded symbols, which lets users compare approaches side by side rather than rely on a single model. Because market regimes shift quickly, the roster is refreshed to reflect what is working now. Reviewing the trending list is a practical starting point for investors who want data-driven signals alongside their own research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
YDES may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 14 of 22 cases where YDES's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 64%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +12.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where YDES advanced for three days, in 53 of 128 cases, the price rose further within the following month. The odds of a continued upward trend are 41%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on YDES as a result. In 36 of 109 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 33%.
The Moving Average Convergence Divergence Histogram (MACD) for YDES turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 58 similar instances when the indicator turned negative. In 19 of the 58 cases the stock turned lower in the days that followed. This puts the odds of success at 33%.
YDES moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where YDES declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
The Aroon Indicator for YDES entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. YDES’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: YDES's P/B Ratio (94.532) is slightly higher than the industry average of (3.592). YDES's P/E Ratio (1383.225) is considerably higher than the industry average of (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (212.766) is also within normal values, averaging (442.120).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. YDES’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology